DTC
ATXS

Deep Track Capital’s Astria Therapeutics ATXS Stock Holding History

Deep Track Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,037,873
Closed -$7.74M – 63
2023
Q3 		$7.74M Sell
1,037,873
-659,542
-39% -$5.62M 0.3% 53
2023
Q2 		$14.1M Sell
1,697,415
-119,116
-7% -$1.37M 0.65% 36
2023
Q1 		$24.2M Hold
1,816,531
– – 0.99% 34
2022
Q4 		$27M Buy
+1,816,531
New +$18.7M 1.14% 31

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Deep Track Capital's ATXS Position: Q4 2023 in Review

Deep Track Capital sold out of Astria Therapeutics (ATXS) in Q4 2023, closing a stake of 1,037,873 shares — an estimated $7.74M sold.

Deep Track Capital first reported a position in ATXS in Q4 2022 and held it in 4 quarters. The position peaked at $27M in Q4 2022. 80 funds tracked by Wall St. Rank hold ATXS as of Q4 2023.

  • Deep Track Capital reported no remaining Astria Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Deep Track Capital sold 1,037,873 Astria Therapeutics shares in Q4 2023, an estimated $7.74M.
  • Deep Track Capital first reported a position in Astria Therapeutics in Q4 2022 and held it in 4 quarters.
  • Deep Track Capital's Astria Therapeutics position peaked at $27M in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2023.

Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.